Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Nature

Volumn 535, Issue 7610, 2016, Pages 148-152

  Chen, Ying Nan P ^a   Lamarche, Matthew J ^a   Chan, Ho Man ^a   Fekkes, Peter ^a   Garcia Fortanet, Jorge ^a   Acker, Michael G ^a   Antonakos, Brandon ^a   Chen, Christine Hiu Tung ^a   Chen, Zhouliang ^a   Cooke, Vesselina G ^a   Dobson, Jason R ^a   Deng, Zhan ^a   Fei, Feng ^a   Firestone, Brant ^a   Fodor, Michelle ^a   Fridrich, Cary ^a   Gao, Hui ^a   Grunenfelder, Denise ^a   Hao, Huai Xiang ^a   Jacob, Jaison ^a   Ho, Samuel ^a   Hsiao, Kathy ^a   Kang, Zhao B ^a   Karki, Rajesh ^a   Kato, Mitsunori ^a   Larrow, Jay ^a   La Bonte, Laura R ^a   Lenoir, Francois ^a   Liu, Gang ^a   Liu, Shumei ^a   Majumdar, Dyuti ^a   Meyer, Matthew J ^a   Palermo, Mark ^a   Perez, Lawrence ^a   Pu, Minying ^a   Price, Edmund ^a   Quinn, Christopher ^a   Shakya, Subarna ^a   Shultz, Michael D ^a   Slisz, Joanna ^a   Venkatesan, Kavitha ^a   Wang, Ping ^a   Warmuth, Markus ^a   Williams, Sarah ^a   Yang, Guizhi ^a   Yuan, Jing ^a   Zhang, Ji Hu ^a   Zhu, Ping ^a   Ramsey, Timothy ^a   Keen, Nicholas J ^a   Sellers, William R ^a   Stams, Travis ^a   Fortin, Pascal D ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; SHP 099; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN P21; PYRIMIDINE DERIVATIVE; SHP099;

BIOAVAILABILITY; CANCER; CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; MUTATION; NUMERICAL MODEL; PATHOLOGY; TUMOR;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALLOSTERIC REGULATION; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASMS; ONCOGENE PROTEIN P21(RAS); PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978416165     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature18621     Document Type: Article

References (29)

1. Grossmann, K. S., Rosario, M., Birchmeier, C. and Birchmeier, W. The tyrosine phosphatase Shp2 in development and cancer. Adv. Cancer Res. 106, 53-89 (2010).
2. Chan, R. J. and Feng, G. S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109, 862-867 (2007).
3. Matozaki, T., Murata, Y., Saito, Y., Okazawa, H. and Ohnishi, H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 100, 1786-1793 (2009).
4. Mohi, M. G. and Neel, B. G. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev. 17, 23-30 (2007).
5. Ostman, A., Hellberg, C. and Bohmer, F. D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6, 307-320 (2006).
6. Gavrieli, M., Watanabe, N., Loftin, S. K., Murphy, T. L. and Murphy, K. M. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. Biophys. Res. Commun. 312, 1236-1243 (2003).
7. Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S. and Honjo, T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14, 1212-1218 (2013).
8. Prahallad, A. et al. PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs. Cell Reports 12, 1978-1985 (2015).
9. Schneeberger, V. E. et al. Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget 6, 6191-6202 (2015).
10. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
11. Scott, L. M. et al. Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. Bioorg. Med. Chem. Lett. 21, 730-733 (2011).
12. Grosskopf, S. et al. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo. ChemMedChem 10, 815-826 (2015).
13. He, R. et al. Exploring the existing drug space for novel pTyr mimetic and SHP2 inhibitors. ACS Med. Chem. Lett. 6, 782-786 (2015).
14. Hellmuth, K. et al. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc. Natl Acad. Sci. USA 105, 7275-7280 (2008).
15. Zeng, L. F. et al. Therapeutic potential of targeting the oncogenic SHP2 phosphatase. J. Med. Chem. 57, 6594-6609 (2014).
16. Pluskey, S., Wandless, T. J., Walsh, C. T. and Shoelson, S. E. Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. J. Biol. Chem. 270, 2897-2900 (1995).
17. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J. and Shoelson, S. E. Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441-450 (1998).
18. Manley, P. W. et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim. Biophys. Acta. 1804, 445-453 (2010).
19. Bender, A. et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2, 861-873 (2007).
20. Szczepankiewicz, B. G. et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. 125, 4087-4096 (2003).
21. Gilmartin, A. G. et al. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. Nat. Chem. Biol. 10, 181-187 (2014).
22. Hoffman, G. R. et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl Acad. Sci. USA 111, 3128-3133 (2014).
23. Shao, D. D. et al. ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 23, 665-678 (2013).
24. Clare, J. J., Tate, S. N., Nobbs, M. and Romanos, M. A. Voltage-gated sodium channels as therapeutic targets. Drug Discov. Today 5, 506-520 (2000).
25. Zhao, H. et al. Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Bioorg. Med. Chem. Lett. 14, 5543-5546 (2004).
26. Kabsch, W. XDS. Acta Crystallogr. D 66, 125-132 (2010).
27. Bricogne, G. et al. BUSTER version 2.8.0. (Global Phasing Ltd., 2009).
28. Emsley, P., Lohkamp, B., Scott, W. G. and Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).
29. Weisberg, E. et al. Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097. Mol. Cancer Ther. 14, 2249-2259 (2015).